Denovo Biopharma
Michael Haller is the current Chief Business Officer at Denovo Biopharma. Prior to this, they served as the Chief Business Officer at Peloton Therapeutics from May 2015 to December 2017. Before that, they were a Board Advisor at GlyTech, Inc. from July 2013 to January 2020. Michael also served as the Vice President of Business Development and Alliance Management at Ligand Pharmaceuticals from August 2012 to April 2013.
Michael Haller received their Ph.D. in Biomedical Engineering from The Johns Hopkins University School of Medicine, their MS in Chemical Engineering from Cornell University, and their BS in Biomedical Engineering from The Johns Hopkins University.
Michael Haller reports to Wen Luo, CEO & CSO. Some of their coworkers include Xiao - Xiong Lu - Chief Technical Officer, Carrie Chen - Chief Financial Officer, and Zan - Dong Yang - Chief Medical Officer.
This person is not in any offices
Denovo Biopharma
Denovo Biopharma is a private San Diego-based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.